194 related articles for article (PubMed ID: 38095092)
1. Risankizumab to treat moderately to severely active Crohn's disease in adults: an evaluation of trials and data.
Johnson AM; Loftus EV
Expert Rev Gastroenterol Hepatol; 2023 Dec; 17(12):1169-1183. PubMed ID: 38095092
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials.
Suleiman AA; Khatri A; Minocha M; Othman AA
Clin Pharmacokinet; 2019 Mar; 58(3):375-387. PubMed ID: 30123942
[TBL] [Abstract][Full Text] [Related]
3. Risankizumab: First Global Approval.
McKeage K; Duggan S
Drugs; 2019 Jun; 79(8):893-900. PubMed ID: 31098898
[TBL] [Abstract][Full Text] [Related]
4. Risankizumab in Adults with Psoriatic Arthritis.
Machlab K; Yeung J; Gooderham M
Skin Therapy Lett; 2023 Nov; 28(6):1-6. PubMed ID: 38015960
[TBL] [Abstract][Full Text] [Related]
5. Risankizumab for the treatment of moderate to severe psoriasis.
Chiricozzi A; Antonioli L; Panduri S; Fornai M; Romanelli M; Blandizzi C
Expert Opin Biol Ther; 2019 Jan; 19(1):1-8. PubMed ID: 30462554
[No Abstract] [Full Text] [Related]
6. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Feagan BG; Sandborn WJ; D'Haens G; Panés J; Kaser A; Ferrante M; Louis E; Franchimont D; Dewit O; Seidler U; Kim KJ; Neurath MF; Schreiber S; Scholl P; Pamulapati C; Lalovic B; Visvanathan S; Padula SJ; Herichova I; Soaita A; Hall DB; Böcher WO
Lancet; 2017 Apr; 389(10080):1699-1709. PubMed ID: 28411872
[TBL] [Abstract][Full Text] [Related]
7. Risankizumab: Mechanism of action, clinical and translational science.
Pang Y; D'Cunha R; Winzenborg I; Veldman G; Pivorunas V; Wallace K
Clin Transl Sci; 2024 Jan; 17(1):e13706. PubMed ID: 38266061
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
9. Risankizumab-rzaa: A New Therapeutic Option for the Treatment of Crohn's Disease.
Choi D; Sheridan H; Bhat S
Ann Pharmacother; 2023 May; 57(5):579-584. PubMed ID: 36214282
[TBL] [Abstract][Full Text] [Related]
10. Risankizumab for the treatment of psoriasis.
Gu C; Yang J
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):851-857. PubMed ID: 31460804
[No Abstract] [Full Text] [Related]
11. Positioning risankizumab in the treatment algorithm of moderate-to-severe Crohn's disease.
Lusetti F; D'Amico F; Allocca M; Furfaro F; Zilli A; Fiorino G; Parigi TL; Radice S; Peyrin-Biroulet L; Danese S
Immunotherapy; 2024 Apr; ():. PubMed ID: 38629330
[TBL] [Abstract][Full Text] [Related]
12. Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials.
D'Haens G; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; Ferrante M
Lancet; 2022 May; 399(10340):2015-2030. PubMed ID: 35644154
[TBL] [Abstract][Full Text] [Related]
13. Update on risankizumab for the treatment of moderate to severe psoriasis.
Al-Janabi A; Warren RB
Expert Opin Biol Ther; 2020 Nov; 20(11):1245-1251. PubMed ID: 32933320
[TBL] [Abstract][Full Text] [Related]
14. Clinical Evaluation of Risankizumab in the Treatment of Adults with Moderately to Severely Active Crohn's Disease: Patient Selection and Reported Outcomes.
Horst S; Cross RK
Drug Des Devel Ther; 2023; 17():273-282. PubMed ID: 36747585
[TBL] [Abstract][Full Text] [Related]
15. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis.
Haugh IM; Preston AK; Kivelevitch DN; Menter AM
Drug Des Devel Ther; 2018; 12():3879-3883. PubMed ID: 30518998
[TBL] [Abstract][Full Text] [Related]
16. Anti-interleukin-12 and anti-interleukin-23 agents in Crohn's disease.
Macaluso FS; Orlando A; Cottone M
Expert Opin Biol Ther; 2019 Feb; 19(2):89-98. PubMed ID: 30571147
[TBL] [Abstract][Full Text] [Related]
17. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.
Ferrante M; Panaccione R; Baert F; Bossuyt P; Colombel JF; Danese S; Dubinsky M; Feagan BG; Hisamatsu T; Lim A; Lindsay JO; Loftus EV; Panés J; Peyrin-Biroulet L; Ran Z; Rubin DT; Sandborn WJ; Schreiber S; Neimark E; Song A; Kligys K; Pang Y; Pivorunas V; Berg S; Duan WR; Huang B; Kalabic J; Liao X; Robinson A; Wallace K; D'Haens G
Lancet; 2022 May; 399(10340):2031-2046. PubMed ID: 35644155
[TBL] [Abstract][Full Text] [Related]
18. A drug safety evaluation of risankizumab for psoriasis.
Huang YW; Tsai TF
Expert Opin Drug Saf; 2020 Apr; 19(4):395-402. PubMed ID: 32100591
[No Abstract] [Full Text] [Related]
19. Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease.
Wong U; Cross RK
Expert Opin Investig Drugs; 2019 May; 28(5):473-479. PubMed ID: 30884245
[TBL] [Abstract][Full Text] [Related]
20. Update on ustekinumab for the treatment of Crohn's disease.
Leung Y; Panaccione R
Gastroenterol Clin North Am; 2014 Sep; 43(3):619-30. PubMed ID: 25110262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]